Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Deftly Defuses Sunscreen, DSHEA Probes In Confirmation Hearing

This article was originally published in The Tan Sheet

Executive Summary

FDA commissioner nominee Robert Califf suggests adequate evidence is key to moving sunscreen TEAs through FDA’s evaluation process during his Senate confirmation hearing. He just as smoothly handled HELP Committee members’ questions about DSEHA and FDA rulemaking.

You may also be interested in...



Sharfstein Suggests Requiring Supplements Registration, Testing Standards

Oversight authorized by DSHEA “is not the regulatory system for dietary supplements sold to the American public,” says former FDA official Joshua Sharfstein.

E.l.f. Facing Off Against Beauty Giants: Third Among Mass Market Brands As Sales Jump 78%

E.l.f. cosmetics climbed to No. 3 brand in US mass market cosmetics, up two slots from a year ago as it surpassed Revlon and CoverGirl. In its recent sales and earnings presentation, it announced sales in its fiscal 2023 fourth quarter jumped 78%.

Cosmetics Industry’s Preservatives Crisis Grows More Dire Under New Washington State Law

Washington State Governor Jay Inslee signed into law HB 1047 on 15 May, implementing the most aggressive cosmetics ingredient ban in the country. The Personal Care Products Council and Independent Beauty Association are concerned about a lack of alternative preservatives to replace targeted formaldehyde-releasing substances effectively and affordably and the law’s inconsistency with FDA over lead levels, among other impacts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel